Meet our dedicated team across research and research infrastructure whose knowledge and wide-ranging skills are critical in underpinning MIA’s world leading research, and gain an insight into their roles and what continues to inspire them.
Angel Guan is a PhD student at Melanoma Institute Australia. Get to know Angel in and out of the lab as she answers questions about herself and her latest work.
Jesse Brown is a PhD student at Melanoma Institute Australia, working at Macquarie University. In this Q&A, we learn about Jesse inside and outside of the lab, from his current projects and future goals to how he spends his downtime.
Dr Andrea Boutros is a Medical Oncology Fellow at Melanoma Institute Australia. Read his Q&A to learn of his inspiring future career goals, his impressive current work, and his surprising hidden talent!
Get to know Dr Tuba Nur Gide in and out of the lab as she answers our questions and gives us a glimpse into her work on developing predictive tools to allow personalised immunotherapy treatment for melanoma.
A/Prof Serigne Lo leads a team responsible for the design & analysis of clinical trials, and the development of tools that guide the treatment of melanoma patients. Let's dive into his life and research!
Meet Dr Jordan Conway, whose crucial research focuses on melanoma metastases in the liver, neoadjuvant immunotherapy and strategies to overcome treatment resistance.
Eva Shteinman is a PhD student in the MIA research team. In our latest Q&A session, we asked Eva everything from how she became a melanoma researcher, to her hidden talents, and more!
Désirée Sexauer is a PhD student at Edith Cowan University in WA, and is a recipient of a MIA Postgraduate Research Scholarship. Read her Q&A.
Dr Camelia Quek is a Postdoctoral Researcher at Melanoma Institute Australia. Camelia answers our questions about her research and personal insights.
Meet Catherine, a PhD student and researcher at MIA. Catherine's current research focus is "Single Cell Spatial Features of In-Transit Melanoma Associated With Patient Outcomes To Immunotherapy".
